Indications and uses
relieves occasional constipation (irregularity) generally causes bowel movement in 6-12 hours
relieves occasional constipation (irregularity) generally causes bowel movement in 6-12 hours
take preferably at bedtime or as directed by a doctor age starting dosage maximum dosage adults and children 12 years of age and over 1 tablet once a day 2 tablets twice a day children 6 to under 12 years 1/2 tablet once a day 1 tablet twice a day children under 6 ask a doctor ask a doctor
Sennosides 17.2 mg
Laxative
Stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. These may indicate a serious condition.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
| age | starting dosage | maximum dosage |
| adults and children 12 years of age and over | 1 tablet once a day | 2 tablets twice a day |
| children 6 to under 12 years | 1/2 tablet once a day | 1 tablet twice a day |
| children under 6 | ask a doctor | ask a doctor |
Inactive ingredients croscarmellose sodium, dicalcium phosphate, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, mineral oil, stearic acid, talc, tartaric acid
©2011, Purdue Products L.P.
Dist. by: Purdue Products L.P., Stamford, CT 06901-3431
302602-0A
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 67618-315-12 | 2023-09-26 | C162847 | 48780-1 | 9d75b9d0-1e5e-f424-e053-dadaa90a57ce | SenokotXTRA (standardized senna concentrate) |
| 67618-315-36 | 2023-09-26 | C162847 | 48780-1 | 9d75b9d0-1e5e-f424-e053-dadaa90a57ce | SenokotXTRA (standardized senna concentrate) |
| 67618-315-12 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-1e5e-f424-e053-dadaa90a57ce | SenokotXTRA (standardized senna concentrate) |
| 67618-315-36 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-1e5e-f424-e053-dadaa90a57ce | SenokotXTRA (standardized senna concentrate) |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 67618-315-12 | EA - Each | 67618-315 | a8497b82-29f0-4b96-aa60-2d38df6863fc | 1 | 2012-07-24 |
| 67618-315-36 | EA - Each | 67618-315 | af35ef27-6e9e-4c43-ad8f-5064f71b0908 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SENNOSIDES | ACTIVE INGREDIENT | 3FYP5M0IJX | 2 | |
| SENNOSIDES | ACTIVE MOIETY | 3FYP5M0IJX | 2 | |
| anhydrous dibasic calcium phosphate | INACTIVE INGREDIENT | L11K75P92J | 2 | |
| anhydrous lactose | INACTIVE INGREDIENT | 3SY5LH9PMK | 2 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| croscarmellose sodium | INACTIVE INGREDIENT | M28OL1HH48 | 2 | |
| hypromelloses | INACTIVE INGREDIENT | 3NXW29V3WO | 2 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| mineral oil | INACTIVE INGREDIENT | T5L8T28FGP | 2 | |
| stearic acid | INACTIVE INGREDIENT | 4ELV7Z65AP | 2 | |
| tartaric acid | INACTIVE INGREDIENT | W4888I119H | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 67618-315 | 67618-315-12, 67618-315-36 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SENNOSIDES | 3FYP5M0IJX | ACTIB |
| croscarmellose sodium | M28OL1HH48 | IACT |
| anhydrous lactose | 3SY5LH9PMK | IACT |
| magnesium stearate | 70097M6I30 | IACT |
| cellulose, microcrystalline | OP1R32D61U | IACT |
| mineral oil | T5L8T28FGP | IACT |
| stearic acid | 4ELV7Z65AP | IACT |
| tartaric acid | W4888I119H | IACT |
| hypromelloses | 3NXW29V3WO | IACT |
| anhydrous dibasic calcium phosphate | L11K75P92J | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| anhydrous dibasic calcium phosphate | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET / ORAL | 2240 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| tartaric acid | TARTARIC ACID | W4888I119H | CAPSULE / ORAL | 400 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | INJECTION / INTRAMUSCULAR | 1 %w/v | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | POWDER, FOR SUSPENSION / ORAL | 11.25 mg | ||
| tartaric acid | TARTARIC ACID | W4888I119H | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 20 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE / ORAL | 72 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | EMULSION / ORAL | NA | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IMPLANT / INTRAVITREAL | 1.66 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| tartaric acid | TARTARIC ACID | W4888I119H | INJECTION / INTRAVENOUS | 20 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | SUSPENSION / ORAL | 150 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 221 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, CHEWABLE / ORAL | 11.8 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | GEL / RECTAL | 348 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | PELLET / SUBCUTANEOUS | 0.97 mg | ||
| anhydrous lactose | ANHYDROUS LACTOSE | 3SY5LH9PMK | CAPSULE, EXTENDED RELEASE / ORAL | 869 mg | ||
| anhydrous dibasic calcium phosphate | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET, FILM COATED / ORAL | 1075 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / ORAL | 305 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 615 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION / ORAL | 1600 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, DELAYED RELEASE PARTICLES / ORAL | 580 mg | ||
| tartaric acid | TARTARIC ACID | W4888I119H | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 20 mg | ||
| tartaric acid | TARTARIC ACID | W4888I119H | SYSTEM / TOPICAL | 349 mg | ||
| anhydrous dibasic calcium phosphate | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | L11K75P92J | TABLET, COATED / ORAL | 333.3 mg | ||
| anhydrous lactose | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 25 mg | ||
| mineral oil | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| anhydrous lactose | ANHYDROUS LACTOSE | 3SY5LH9PMK | TABLET, COATED / ORAL | 560 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, EXTENDED RELEASE / ORAL | 53 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| anhydrous lactose | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 375 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, EXTENDED RELEASE / ORAL | 392 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 144 mg | ||
| hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED / ORAL | 582 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| stearic acid | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2c66fb30-7e35-65c0-395e-117a737b24ea | f27cb405-9820-4fe9-8432-e50643f2c7f0 | 2023-09-04 | Warnings | f27cb405-9820-4fe9-8432-e50643f2c7f0 |
Adverse event summaries are temporarily unavailable. Other product information remains available.